DJIA 17,888.35 168.43 0.95%
NASDAQ 5,156.31 47.64 0.93%
S&P 500 2,102.63 22.22 1.07%
market minute promo

Exelixis (NASDAQ: EXEL)

5.76 0.04 (0.70%)

REAL-TIME: Last trade at

Extended Hours: $5.76 $0.00 (-0.02%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

EXEL $5.76 0.70%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.73
Previous Close $5.72
Daily Range $5.52 - $5.79
52-Week Range $1.26 - $6.81
Market Cap $1.3B
P/E Ratio -6.29
Dividend (Yield) $0.00 (0.0%)
Volume 6,403,523
Average Daily Volume 3,841,668
Current FY EPS -$0.85




Drug Makers

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary Rss Feed

The FDA Approves Exelixis, Inc's New Cancer Drug

The Swiss are on the offensive against cancer.

US Regulator Slows Down The Immuno-Oncology Runaway Train

Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod

Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination wit

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

Did You Miss These Top Stories in Healthcare?

Last week's most exciting healthcare news: Exelixis nets a win, and Colorado takes aim at health insurers.

Exelixis, Inc. Earnings: Riding the Meteor

The biotech is still burning cash, but with data in hand, there's an opportunity for a solid revenue stream shortly.

6 Stocks That Could Double In 2016

If you have some extra cash and want to take a chance, these six stocks have the potential for excellent returns.

Are Investors Nuts To Be Short These Stocks?

Short sellers think shares in these stocks will go lower because catalysts are unlikely to support their lofty valuations.

See More EXEL News...

EXEL's Top Competitors

EXEL $5.76 (0.70%)
Current stock: EXEL
TMO $138.35 (-0.04%)
Current stock: TMO
ILMN $187.48 (1.95%)
Current stock: ILMN
WAT $133.38 (0.42%)
Current stock: WAT